Yongxing "James" Liu

Yongxing "James" Liu has a diverse work experience in the field of bioengineering and regenerative medicine. Yongxing "James" is currently the Director of Bioengineering at BioRestorative Therapies, Inc., where they are responsible for leading the development of new products and regenerative medicines targeting orthopedic, metabolic, and endocrine disorders. Their role also includes cGMP production of cellular therapeutics, regulatory submission, and the establishment of strategic collaborations and fundraising.

Prior to their current position, James served as the VP for Research at Innovative Elements LLC from 2014 to 2018. Before that, they worked as a Senior Scientist at the same company from 2013 to 2014. Yongxing "James" also held the concurrent post of Executive Director at Suzhou Regenerative Medicine, Suzhou from 2015 to 2017.

James has also contributed to the academic field, working as an Assistant Professor and Researcher at Missouri S&T from 2011 to 2013, and at the University of Notre Dame from 2010 to 2011. Yongxing "James" started their career as a Research Fellow at the University of Connecticut Health Center from 2008 to 2010, where they made significant contributions in the field of mesenchymal stem cell derivation, cell-biomaterials interactions, and tissue regeneration. Yongxing "James" also gained valuable experience as a Postdoc Trainee at the University of Tennessee Health Science Center from 2005 to 2007.

Overall, James Liu's work experience demonstrates their expertise in bioengineering, regenerative medicine, cellular therapeutics, and academic research.

Yongxing "James" Liu completed their postdoctoral studies in stem cell biology and regenerative medicine at The University of Connecticut Health Center from 2008 to 2010. Prior to that, they obtained their PhD in the Division of Biotechnological and Pharmaceutical Science from Okayama University in Japan from 2001 to 2005. The field of study for their PhD is not specified.